The purpose of this Phase 1 study is to test the safety and tolerability of LY3819253 when it is given by injection into a vein to participants hospitalized with COVID-19. Blood tests will be done to check how much LY3819253 is in the bloodstream and how long the body takes to eliminate it.

Participation could last about 8 weeks and may include up to 15 visits in the hospital or the home.